{"name":"Consorzio per Valutazioni Biologiche e Farmacologiche","slug":"consorzio-per-valutazioni-biologiche-e-farmacologiche","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Deferiprone, dose level 2","genericName":"Deferiprone, dose level 2","slug":"deferiprone-dose-level-2","indication":"Beta-thalassemia major","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Deferiprone, dose level 3","genericName":"Deferiprone, dose level 3","slug":"deferiprone-dose-level-3","indication":"Treatment of beta-thalassemia major","status":"phase_2"}]}],"pipeline":[{"name":"Deferiprone, dose level 2","genericName":"Deferiprone, dose level 2","slug":"deferiprone-dose-level-2","phase":"phase_2","mechanism":"Iron chelator","indications":["Beta-thalassemia major","Sickle cell disease"],"catalyst":""},{"name":"Deferiprone, dose level 3","genericName":"Deferiprone, dose level 3","slug":"deferiprone-dose-level-3","phase":"phase_2","mechanism":"Deferiprone chelates iron, reducing its accumulation in tissues.","indications":["Treatment of beta-thalassemia major","Treatment of other iron overload conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQd2c0d3RsV3B3U2pHMWlpaFBYczlyS1gzTld3VlVRY3R5MFZOOU00UHVsV3ZGMTZ5VFhIcGVGTjdmTXd5U0ZMWG12cWZ1VnB4N1Z4YTVtbTF1dEl4RTlqYUF5UXhVSUNnZ085a2xKaUNOVjZRQlRjVDlWaWxJbDRWS0Z2dV9kdTZrNVJIWTBrOE9lRW5xbWY4bUM4cnFvUGM5ZU1feWgyN1FqckV0NjJBZg?oc=5","date":"2025-02-28","type":"trial","source":"portale.units.it","summary":"Rett syndrome: the University of Trieste will coordinate the world's first trial of Mirtazapine - portale.units.it","headline":"Rett syndrome: the University of Trieste will coordinate the world's first trial of Mirtazapine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQNDNTSHdGNlBudkEzYzg2VHNubWdTVlFVb3NnR21YdDItUG9ENlFBY2ItTUNaaWpkbWswcW13S0hjOXVZZE9WbTdDQ2tGYjdrb2Y1LTJqMC1oamdLVmQzOGlQUFpZWGh0NU13WkRQNVV0QklvaE01dkttdHBPeVhZMjAyRVhzZkRTRzZOdWEtNS12ekd0?oc=5","date":"2023-11-27","type":"pipeline","source":"Frontiers","summary":"Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries - Frontiers","headline":"Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}